Incyte Corporation (INCY) Performance:43.91%(TTM)
The total return for Incyte Corporation (INCY) stock is +43.91% over the past 12 months vs. +26.77% for the S&P 500. So far it's up -0.56% this year. Includes price appreciation + reinvested dividends.
Incyte Corporation (INCY) Compound Annual Growth Rates (CAGR) Summary
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +43.91% | +15.78% | +3.19% | +2.45% | +12.00% | +17.29% |
| Total Return CAGR | +43.91% | +15.78% | +3.19% | +2.45% | +12.00% | +17.29% |
| Revenue CAGR | +21.48% | +15.60% | +14.68% | +20.11% | +25.18% | +36.03% |
| Net Income CAGR | +6631.44% | +64.02% | +24.51% | +40.17% | +24.45% | +24.45% |
| EPS CAGR | +4029.25% | +62.69% | +21.19% | +66.59% | +18.66% | +18.66% |
| Free Cash Flow CAGR | +402.37% | +37.27% | +20.60% | +24.62% | +19.67% | +28.67% |
| Operating Cash Flow CAGR | +296.45% | +32.73% | +14.68% | +23.18% | +19.69% | +14.54% |
| Dividends CAGR | - | - | - | - | - | - |
CAGR Trends History
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
INCY Total Return CAGR Chart
Incyte Corporation (INCY)
Annual Total Returns Comparison
| Year | Start Value | End Value | INCY Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | 1162.00 | 1155.53 | (0.56%) | +10.09% | (10.65%) |
| 2025 | 812.59 | 1162.00 | +43.00% | +17.72% | +25.28% |
| 2024 | 738.71 | 812.59 | +10.00% | +24.89% | (14.89%) |
| 2023 | 944.94 | 738.71 | (21.83%) | +26.19% | (48.02%) |
| 2022 | 863.53 | 944.94 | +9.43% | (18.17%) | +27.60% |
| 2021 | 1023.29 | 863.53 | (15.61%) | +28.74% | (44.35%) |
| 2020 | 1027.29 | 1023.29 | (0.39%) | +18.37% | (18.76%) |
| 2019 | 748.12 | 1027.29 | +37.32% | +31.22% | +6.10% |
| 2018 | 1114.24 | 748.12 | (32.86%) | (4.56%) | (28.30%) |
| 2017 | 1179.65 | 1114.24 | (5.55%) | +21.70% | (27.25%) |
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury